Targeting the Gut Microbiota in Chagas Disease: What Do We Know so Far? by Duarte-Silva, Eduardo et al.
fmicb-11-585857 December 5, 2020 Time: 21:24 # 1
REVIEW







Institute of Studies on Humoral
Immunity (IDEHU), Argentina
Thomas Jacobs,








This article was submitted to
Microbial Immunology,
a section of the journal
Frontiers in Microbiology
Received: 21 July 2020
Accepted: 12 November 2020
Published: 10 December 2020
Citation:
Duarte-Silva E, Morais LH,
Clarke G, Savino W and Peixoto C
(2020) Targeting the Gut Microbiota




Targeting the Gut Microbiota in
Chagas Disease: What Do We Know
so Far?
Eduardo Duarte-Silva1,2,3* , Livia H. Morais4, Gerard Clarke5,6, Wilson Savino7,8 and
Christina Peixoto1,7*
1 Laboratory of Ultrastructure, Aggeu Magalhães Institute (IAM), Oswaldo Cruz Foundation (FIOCRUZ-PE), Recife, Brazil,
2 Postgraduate Program in Biosciences and Biotechnology for Health (PPGBBS), Aggeu Magalhães Institute (IAM), Recife,
Brazil, 3 Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education
and Research Network (USERN), Recife, Brazil, 4 Division of Biology and Biological Engineering, California Institute
of Technology, Pasadena, CA, United States, 5 Department of Psychiatry and Neurobehavioural Science, University College
Cork, Cork, Ireland, 6 APC Microbiome Ireland, University College Cork, Cork, Ireland, 7 National Institute of Science
and Technology on Neuroimmunomodulation (INCT-NIM), Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro,
Brazil, 8 Laboratory on Thymus Research, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil
Chagas disease (CD) is a tropical and still neglected disease caused by Trypanosoma
cruzi that affects >8 million of people worldwide. Although limited, emerging data
suggest that gut microbiota dysfunction may be a new mechanism underlying CD
pathogenesis. T. cruzi infection leads to changes in the gut microbiota composition
of vector insects, mice, and humans. Alterations in insect and mice microbiota due to
T. cruzi have been associated with a decreased immune response against the parasite,
influencing the establishment and progression of infection. Further, changes in the
gut microbiota are linked with inflammatory and neuropsychiatric disorders, comorbid
conditions in CD. Therefore, this review article critically analyses the current data on
CD and the gut microbiota of insects, mice, and humans and discusses its importance
for CD pathogenesis. An enhanced understanding of host microbiota will be critical
for the development of alternative therapeutic approaches to target CD, such as gut
microbiota-directed interventions.
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INTRODUCTION
Chagas disease (CD), also known as American trypanosomiasis, is a malady that affects >8 million
people worldwide (Lidani et al., 2019) resulting in high socioeconomic burden to our society (Lee
et al., 2013). Although it was discovered more than 100 years ago by Carlos Chagas and comes
with a high health burden (Chagas, 1909; Lee et al., 2013), it continues to be a neglected disease
(Schofield et al., 2006; Clayton, 2010). The flagellate protozoan Trypanosoma cruzi (T. cruzi) is the
causative agent of CD, and it is primarily transmitted to humans and animals via insect vectors
known as triatomines. CD is more prevalent and endemic in Latin American countries. However,
more recently, other non-endemic areas, such as United States, Canada, Europe, Australia, and
Japan are starting to be affected by CD due to increased immigration world-wide (Gascon et al.,
2010; Jackson et al., 2014). It is thought that CD burden could be attenuated with disease control
approaches, including vector control and treatment of the infection at an early stage (Schofield
et al., 2006; Gascon et al., 2010).
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Infection symptoms include inflammation in the
gastrointestinal tract (GIT) and heart dysfunctions and may
also include neurological and behavioral disturbances (Prata,
2001; Marchi and Gurgel, 2011; Ozaki et al., 2011; Vilar-Pereira
et al., 2015; Pérez-Molina and Molina, 2018). Interestingly,
recent evidence now suggests an involvement of other biological
factors that may contribute to mechanisms underpinning CD
pathophysiology. For instance, the role of the gut microbiota
in CD has been reported by preclinical and clinical studies
(Duarte et al., 2004, 2005; McCall et al., 2018; Robello et al., 2019;
De Souza-Basqueira et al., 2020). Gut microbiota alterations have
been found in triatomine insects, mice, and human hosts (Duarte
et al., 2004, 2005; Garcia et al., 2007; Díaz et al., 2016; McCall
et al., 2018; Robello et al., 2019). For example, alterations in the
gut microbiota of triatomine insects, including changes in the
Enterobacteriaceae and Nocardiaceae family as well as low CFU
counts, may increase the susceptibility to infection by impairing
immune response against T. cruzi (Castro et al., 2012; Vieira
et al., 2016). It is possible that gut microbiota alterations induced
by T. cruzi may aggravate the host’s pathology due to modulation
of the immune system (Díaz et al., 2016). However, the impact of
the gut microbiota on CD’s pathophysiology remains to be fully
understood. In this review, we critically analyze the current data
associating CD and the gut microbiota and the importance of this
interaction for CD pathogenesis. An enhanced understanding of
this relationship will be critical for the development of alternative
therapeutic approaches for CD treatment.
CHAGAS DISEASE TRANSMISSION AND
INFECTION CYCLE
The mode of CD transmission varies according to geography
(Lidani et al., 2019). In Latin America, it is mainly transmitted
via insect vectors known as triatomines, which are infected
with the parasite after a blood meal from infected humans or
other animals, according to the parasite’s life cycle (Figure 1).
In non-endemic places, blood transfusion, organ donation,
congenital transmission during pregnancy, or via oral route
with contaminated food and water are the main modes of
CD transmission (Lidani et al., 2019). After infection with
T. cruzi the disease can follow two distinct phases. In the
acute phase, an increased parasitemia is observed. Although
at this stage the disease is usually asymptomatic, there may
be a few symptoms, such as fever, inflammation, tachycardia,
fatigue, which can spontaneously disappear in most patients
(Prata, 2001; Clayton, 2010; Pérez-Molina and Molina, 2018;
Lidani et al., 2019). The chronic phase of the disease affects
one third of the patients and begins with a latency period
known as the indeterminate form of CD. This can persist
for more than 30 years or throughout life unnoticed. After
that phase, some patients can develop a symptomatic phase in
which a decline in parasitemia and neurological, cardiac and
digestive manifestations are observed as well as neuropsychiatric
comorbidities and behavioral changes (Prata, 2001; Hueb and
Loureiro, 2005; Clayton, 2010; Marchi and Gurgel, 2011;
Ozaki et al., 2011).
THE GUT MICROBIOTA
The gut microbiota comprises a community of bacteria, archaea,
fungi, and viruses that has co-evolved with their hosts over
thousands of years to form intricate commensal relationships
(Rinninella et al., 2019). The bacterial cell number present in
the human gut has been estimated to be around 3.8 × 1013,
which is similar to our cell number in the body (Sender et al.,
2016). Although the number of bacterial species is high, most
of them belong to Firmicutes, Bacteroidetes, and Actinobacteria
phyla (Falony et al., 2016). The gut microbiome interacts with
host essential physiological processes such as modulation of
immune system, metabolism, and neurotransmission, which
ultimately coordinate host homeostasis (Keely, 2017). Regarding
immunity, it is known that the gut microbiota modulates the
development of CD8+ T cells, lymphocytes with key roles in
the control of T. cruzi (Martin and Tarleton, 2004; Acosta
Rodríguez et al., 2019). Gut microbiota changes with antibiotic
treatment were associated with altered cytokine response and
T cell receptor (TCR) signaling in CD8+ T cells (Gonzalez-
Perez and Lamousé-Smith, 2017). Furthermore, certain strains
of gut bacteria are able to induce CD8+ T cells in the intestine,
which is associated with enhanced immunity against Listeria
monocytogenes and enhanced anti-tumor activity (Tanoue et al.,
2019). The contribution of the gut microbiome to human
health and disease continues to be unraveled. However, in the
recent years, large-scale studies using emerging technologies in
microbiome research, including 16S ribosomal RNA (rRNA)
sequencing for taxonomic characterization and whole genome
shotgun (WGS) metagenomic sequencing for genomic and
metabolic functional analysis are accelerating the discovery of
new links between the gut microbiome, human health, and
disease (Kho and Lal, 2018).
The gut microbiota signals to their host using metabolic
products, neurotransmitters, cytokines, and anti-microbial
substances (Fischbach and Segre, 2016). On the microbiota side,
one of the most studied mediators of this communication are
bioactive molecules named short-chain fatty acids (SCFAs),
which consist of bacterial-derived dietary fermentation products.
The most common SCFA are acetate, propionate, and butyrate.
SCFAs can modulate host cell functions by controlling gene
transcription through epigenetic pathways, through the
activation of “metabolite-sensing” G-protein coupled receptors
(GPCRs) or indirectly via interactions with host’s energetic
metabolism and immune system (Wilson, 2005; Smith et al.,
2013). Importantly, acetate, the most abundant SCFAs present in
the blood circulation, influences cardiac function such as blood
pressure and heart rate in mice via at least two modes: renin
release in the juxtaglomerular apparatus and changes in vascular
tone in the periphery (Onyszkiewicz et al., 2020). Furthermore,
butyrate can inhibit histone-deacetylases (HDACs), affecting the
gene expression of CD8+ cytotoxic T cells (CTLs) and causes an
increase in the expression of interferon-γ (IFN-γ) and granzyme
B in this cell population (Luu et al., 2018).
Another key mediator factor between the gut microbiota
and their hosts is the immune system. The gut microbiota is
known to direct the immune system maturation, development,
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FIGURE 1 | Schematic summarizing the life cycle of Trypanosoma cruzi. (1) Triatomine bugs take a blood meal and passes metacyclic trypomastigotes in their feces,
which then enter the host via bite wounds or mucosal membranes. Metacyclic trypomastigotes now invade host cells (not shown) and become amastigotes, which
multiple inside the infected cells (2). Amastigotes then transform into trypomastigotes, which then cause cell lysis and their release into the bloodstream (3).
Triatomine bugs become infected when they feed on an infected mammalian host (4). Inside the insect vector, trypomastigotes now transform into epimastigotes in
the insect gut (5). Finally, epimastigotes transform into infective metacyclic trypomastigotes (6), which are released in the feces and the cycle re-starts.
and response. Specific gut microorganisms named segmented
filamentous bacterium, non-culturable Clostridia-related species,
guide the development of hosts IL-17 (Th17) and IFNγ
(Th1) T cells in the gut mucosal immune system of rodents
(Gaboriau-Routhiau et al., 2009; Hooper et al., 2012). Further,
colonization of germ-free (GF) mice (mice born and raised
without microbiome) with commensal microbiota induces IgA
in intestinal dendritic cells, further affecting hosts defense against
non-pathogenic and pathogenic microorganisms. Microbial
signaling to host immune system is also facilitated by microbial
metabolites and by bacterial products such as SCFAs and
polysaccharide (PSA), among others (Kim et al., 2013; Macia
et al., 2015). From the host side, signals are sent via
hormones, cytokines, anti-microbial products, which will further
change gut microbial communities’ structure and function
(Fischbach and Segre, 2016). Thus, it is not surprising that
such intricate relationship between the gut microbiota and
their hosts are implicated in many diseases, ranging from
inflammatory and cardiovascular diseases, metabolic, psychiatric,
and neurological conditions. The bidirectional communication
between the microbiota and other physiological systems of
the body, such as the nervous, endocrine, and immune
system collectively form the microbiota-gut-brain axis (Cryan
et al., 2019). This constant crosstalk allows the host to
maintain homeostasis of essential physiological processes, such
as neurotransmission, appetite, neuroprotection, neurogenesis,
which ultimately coordinate behavior. Data now available
demonstrate that dysfuncion in the gut microbiota homeostasis
play a role in many chronic inflammatory, neuroinflammatory,
and neuropsychiatric disorders (Burokas et al., 2015; Sherwin
et al., 2016; Sandhu et al., 2017). However, the role of the
gut-microbiota-brain axis in CD remains largely unknown.
Therefore, the exploring its role could provide new insights into
CD pathophysiology and treatment.
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THE GUT MICROBIOTA IN CHAGAS
DISEASE
Microorganisms that inhabit the gut of vector insects have a
pivotal role in the modulation of vector competence, which is
“the ability to acquire, maintain, and transmit pathogens” (Lane,
1994). These microbes can interfere with vector competence
either directly or indirectly (Dillon and Dillon, 2004; Azambuja
et al., 2005; Garcia et al., 2007, 2010; Cirimotich et al., 2011;
Weiss and Aksoy, 2011). In the first case, they interact with
parasites and compete for resources present in the triatomine
gut. In the second case, the triatomine gut microbiota can trigger
anti-parasitic mechanisms and immune responses against the
parasite, modulating parasite transmission (Dillon and Dillon,
2004; Azambuja et al., 2005; Garcia et al., 2007, 2010; Cirimotich
et al., 2011; Weiss and Aksoy, 2011). A study that characterized
triatomine bacterial communities demonstrated that T. cruzi
infection changes the gut microbiota of these insects and it
depends on “the intrinsic qualities” of the parasite itself, the
insect vector and the gut microbiota of the host (Díaz et al.,
2016). In the laboratory setting, the triatomine gut microbiota
is characterized by low diversity of microbial population and
dominance of one or few genera and specificity of bacteria
to some triatomine hosts, which means that some genera of
bacteria are found in specific hosts but not all host species
(Díaz et al., 2016).
GUT MICROBIOTA ALTERATIONS IN
CLINICAL AND EXPERIMENTAL CD: A
NEW PLAYER IN CD PATHOGENESIS?
Vector–Parasite–Microbiota Interaction
in Mice and Humans
Over the years, studies focusing primarily on the parasite-vector
and parasite-host cell interaction have been performed, and much
insight regarding T. cruzi infection establishment and disease
progression was gained following this approach (De Souza et al.,
2010; De Oliveira et al., 2018). Nonetheless, given the crucial role
the microbiota has to the host itself, the studies herein discussed
focused on a tripartite interaction known as the “vector–parasite–
microbiota interaction,” which is an approach that considers the
gut microbiota of the host as relevant to disease establishment
and progression (Díaz et al., 2016). The idea that gut microbiota
was somehow linked to CD was previously hypothesized in
a series of studies using GF mice. An early study comparing
the impact of acute Y strain of T. cruzi infection on GF mice
and conventional mice demonstrated that the absence of gut
microbiota in the GF mice leads to a much more severe course of
infection (Silva et al., 1987). A possible reason for these outcomes
is that, as showed in another study, acutely infected mice also had
an impaired cellular and humoral-mediated immune response
against the parasite, as observed by lowered levels of IFN-γ,
TNF-α, nitric oxide (NO), and antibodies specifically generated
against T. cruzi antigens (anti-T.cruzi IgG1 and IgG2a) (Duarte
et al., 2004). These findings are in keeping with the fact that the
microbiome educates and shapes the immune system (Lee and
Mazmanian, 2010; Hooper et al., 2012).
Consequently, it is expected that GF mice have an immature
immune system and therefore display an altered immune
response to an immune challenge. It should be noted that
these studies do not offer a causal association between the gut
microbiota and CD, but rather demonstrate the importance
of the gut microbiota on priming the immune response in
the context of parasitic diseases. Whether specific members of
the microbial community contribute to the modulation of CD
remains to be determined.
In a preliminary attempt to answer this question, a sequence of
studies investigated the role of specific gut bacteria on mediating
immunomodulatory effects in the host following acute exposure
to T. cruzi (Silva et al., 1987; Duarte et al., 2004). In a study, GF
Swiss mice received a single intragastric and individual injection
of Escherichia coli, Enterococcus faecalis, Bacteroides vulgatus, or
Peptostreptococcus sp. 10 days prior to infection with 5 × 103
T. cruzi trypomastigotes (Y strain) (Please refer glossary). The
authors found that gnotobiotic mice had increased survival rates
when compared to control GF mice (Duarte et al., 2005), which
tend to die earlier after infection (Silva et al., 1987). Conversely,
a separate study demonstrated that monocolonization with
Bacteroides fragilis, Clostridium sp., and even Peptostreptococcus
sp. were associated with earlier mortality in acute experimental
CD (Barros et al., 1992). The results for Bacteroides fragilis are
undoubtedly surprising, since polysaccharide A (PSA) derived
from this bacterium has modulatory effects on the immune
system, driving its maturation and balance of Th1/Th2 responses
in mice (Mazmanian et al., 2005), which would be ideal for
T. cruzi infection resolution. The reasons for these apparently
contradicting data are hitherto undefined, buy may be due to
a more Th2-associated response, which consequently promotes
parasite’s persistence in the host.
Interestingly, increased levels of NO were only observed
in E. coli and Peptostreptococcus sp.-associated mice, while
the lowest and highest production of IgG1 and IgG2a
levels, respectively, were only shown in Peptostreptococcus sp.-
associated mice. Furthermore, only mice that received E. faecalis
had a rise in IL-10 in cultured splenocytes. These findings suggest
that some of the observed immunomodulatory effects depends
on certain bacterial species and cannot be generalized (Duarte
et al., 2005). In fact, immunomodulation is a well recognized
feature of commensal gut bacteria, contributing not only to
mucosal immunity, but also to immune tolerance (Donaldson
et al., 2015; Libertucci and Young, 2019). Collectively, these data
demonstrate that colonization of the gut with specific bacteria
strains normalizes the immune function, allowing the host to
respond to T. cruzi.
The studies so far reported only showed that the gut
microbiota has a role in immune homeostasis, which is
important for the resolution of acute infection with parasites
in general. However, a recent study using male C3H/HeJ
mice infected with a luciferase-expressing T. cruzi strain (CL
Brener) demonstrated a more direct association between T. cruzi
infection and gut microbiota alterations. In this study, the
authors sampled fecal pellets twice a week during the acute
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phase and every 2–3 weeks during the chronic phase. Using
16s rRNA sequencing it became evident that T. cruzi infection
was associated with changes in Bacteroidales and Clostridiales
order, which belong to Bacteroidetes and Firmicutes phyla.
Further, host fecal metabolic status was assessed using ultra-high
performance liquid chromatography tandem mass spectrometry
(UHPLC-MS/MS) and revealed alterations in fatty acids and
bile acids metabolism in mice infected with the parasite
(McCall et al., 2018).
More pronounced differences between groups were found at
21-days post-infection. Linoleic and linolenic acids are fatty acids
metabolized by gut bacteria, including by members of the family
Ruminococcaceae and Lachnospiraceae (phylum Firmicutes) that
are present in the mice cecum and feces (Gu et al., 2013),
into conjugated linoleic and linolenic acid and other derivative
molecules, such as vaccenic acid (Zhang and Davies, 2016).
These metabolites have been associated with anti-inflammatory
response in other disease models such as animal models of
colitis (Bassaganya-Riera et al., 2004; Miyamoto et al., 2015) and
colorectal cancer (Evans et al., 2010). For instance, in colitis
animal models, linoleic acids can act locally by downregulating
the TNF-α receptor (Miyamoto et al., 2015) and TNF-α
expression (Bassaganya-Riera et al., 2004) and upregulating
production of anti-inflammatory cytokine TGF-β in the colon
(Bassaganya-Riera et al., 2004). Moreover, they decrease the
infiltration of immune cells in the colon of mice with colorectal
tumors, while increasing the number of regulatory T cells (Tregs)
in the mesenteric lymph node (Evans et al., 2010).
Thus, a plausible possibility is that changes in the gut
microbiome composition and consequently fecal metabolite
alteration may favor T. cruzi survival through inducing an
anti-inflammatory response in the host (McCall et al., 2018).
However, whether these outcomes are relevant to humans with
CD is still a matter of debate. Moreover, primary bile acids are
produced by the host and further modified by the gut bacteria,
including members of Clostridiales order or from the genus
Bifidobacterium or Lactobacillus, to generate secondary bile acids
(2BAs) such as deoxycholic acid. Changes in the metabolism of
bile acids are associated with inflammation in the GIT (Gérard,
2013), but its role in CD remains poorly understood. Taken
together, experimental CD leads to changes in bacteria that
modulate fatty acids and bile acid metabolism in mice and these
fecal microbiome and metabolome changes may be relevant for
the persistence of T. cruzi in the host.
A recent study was conducted with twenty Bolivian children
who were diagnosed with CD and treated with benznidazole,
a CD first line treatment drug (Robello et al., 2019). Fecal
samples were obtained before and after treatment and 16s
rRNA sequencing was used to analyze the microbiota and
uninfected subjects were used as controls. It was observed that the
parasite induced changes not only in the gut microbiota of these
individuals, but also in the skin microbiota. T. cruzi infection
was associated with high amounts of fecal Prevotella (phylum
Bacteroidetes), Ruminococcaceae and Succinivibrio (phylum
Proteobacteria). In humans, Prevotella was associated with
increased plasma levels of trimethylamine-N-oxide (TMAO),
a molecule implicated in cardiovascular disease (Koeth et al.,
2013). Overall, infected children had increased Firmicutes
and lowered Bacteroides, despite variations in age and diet
(Robello et al., 2019).
Another study employing next generation sequencing (NGS)
to investigate the gut microbiota composition of one hundred
and fourteen Brazilian individuals with different forms of
chronic CD also confirmed that T. cruzi triggers human
gut microbiota changes (De Souza-Basqueira et al., 2020). In
this study, thirty patients had the cardiac form, eleven had
the digestive form, thirty-two had the indeterminate form
and thirty-one were healthy individuals. The authors found
lowered levels of Verrucomicrobia phylum as well as decrease
in Veillonellaceae family (phylum Firmicutes) and Dialister
genera (phylum Firmicutes) in patients with cardiac CD.
Indeterminate CD patients had lowered Bacteroidaceae family
(phylum Bacteroidetes), specifically Bacteroides genera when
compared to controls. Patients with digestive form of CD
and megacolon had reduction in Lachnospiraceae family but
increase in Porphyromonadaceae family (phylum Bacteroidetes)
(De Souza-Basqueira et al., 2020).
Overall, all the main gut bacteria phyla play a prominent
role in colonization resistance, but some members may also be
involved in inflammation. For example, Lactobacillus spp. from
the Firmicutes phylum are able to inhibit C. difficile colonization
and reduce inflammation, while segmented filamentous bacteria
(SFB), also from the Firmicutes phylum, induce the secretion
of antimicrobial peptides (AMPs), pro-inflammatory cytokines
and IgA, as well as trigger the development of CD4+ T helper
17 (TH17) cells (Buffie and Pamer, 2013). Besides, studies now
suggest that changes in the gut microbiota community may
be associated with increased infection susceptibility (Libertucci
and Young, 2019). However, since our understanding of the
microbiota in CD is still in its infancy, studies are yet required to
clarify the role of certain microorganisms in determining higher
susceptibility to infection or even infection clearance, since many
of them may present trypanolytic activity and therefore are vital
for CD modulation.
Taken together, the aforementioned data show that T. cruzi
infection is followed by changes in the gut microbiome
and metabolome, which might be important for the parasite
persistence in the host. Besides, the importance of other
microbiota (oral and skin) to the pathogenesis of CD is
also highlighted and deserves to be more defined in future
studies. Nonetheless, these studies are preliminary and did not




Studies performed with triatomine vectors are also important
to our current understanding of the role of the gut microbiota
in CD. For example, a study was conducted to determine
the microbiota changes that results from T. cruzi infection in
Rhodnius prolixus, a vector of T. cruzi (Castro et al., 2012). In
this study, R. prolixus were fed rabbit blood with or without the
Dm28c clone of T.cruzi, which can complete its developmental
cycle in the insect gut (Vieira et al., 2016). After insects were
fed with blood, analyses of the gut microbiota using colony
Frontiers in Microbiology | www.frontiersin.org 5 December 2020 | Volume 11 | Article 585857
fmicb-11-585857 December 5, 2020 Time: 21:24 # 6
Duarte-Silva et al. Chagas Disease and Gut Microbiota
forming unit (CFU) assay were performed from day 5 to 29,
as well as antibacterial and phenoloxidase (PO) assays and
NO measurement. Insects that were infected with T. cruzi
presented low gut microbiota population as revealed by less CFU
numbers in the agar plates (Vieira et al., 2016). Interestingly, a
similar study using the same T. cruzi strain showed that after
infection there were lower CFU counts and reduced numbers of
Serratia marcescens (Enterobacteriaceae family), a bacterium with
trypanolytic activity (Da Mota et al., 2019). Furthermore, reduced
numbers of Rhodococcus rhodnii were also reported (Vieira et al.,
2016). This bacterium belongs to Nocardiaceae family and helps
in the processing of B vitamins in the triatomine’s gut (Rodríguez
et al., 2011; Pachebat et al., 2013).
Accordingly, another study showed that infection of six
different species of T. cruzi vectors (P. megistus, R. prolixus,
T. brasiliensis, T. infestans, T. juazeirensis, and T. sherlocki) with
T. cruzi epimastigotes strain 0354 resulted in changes in gut
microbiota community depending on the studied hosts, in a
“species-specific manner,” as well as in increased diversity in
gut microbiota as demonstrated by 16s rRNA sequencing (Díaz
et al., 2016). Furthermore, the gut antimicrobial activity was
increased in T.cruzi-infected insects, as measured by inhibition
zone and turbidometric assay (Castro et al., 2012). However, the
antimicrobial activity did not result in the parasite’s elimination
and it is rather explained by reduction in the microbial
population, leading to low microbiota population (Castro et al.,
2012). Moreover, the activity of PO, an important enzyme of
the innate immune system of insects, and NO, an immune
system mediator, were also investigated (Castro et al., 2012).
The authors found that, PO activity levels were elevated and
NO was decreased in infected insects. However, the increase in
PO did not correlate with reduction of parasite density in the
gut (Castro et al., 2012). Although PO activity levels were not
enough for killing the parasite, it may be linked with changes
in gut microbiota composition observed in the vector insects.
These studies highlights that (i) T.cruzi interacts with triatomine
vector microbiome and causes changes in the microbiome; (ii) the
microbiome seems to be important for control of T. cruzi, since
antibiotic treated insects had higher parasite density in the gut
(Castro et al., 2012); (iii) vectorial competence may be associated
with microbiota profile of vector insects; (iv) the microbiota
changes observed after T.cruzi infection alter vector immunity.
In sum, insects studies show that T. cruzi infection is
associated with changes in the gut microbiota, especially
reduction in bacterium with trypanolytic activity and increased
diversity of gut microbiota. T. cruzi infection also increased the
secretion of AMPs, leading to a reduction in the gut microbiota
community, rather than eliminating the parasite.
MICROBIOTA, CD, AND ITS
COMORBIDITIES
As already discussed, heart inflammation is a key feature of
CD. Interestingly, data are now suggesting that microbial-derived
molecules and metabolites, such as microbe-associated molecular
patterns (MAMPS), SCFAs, 2BAs, and TMAO may underpin
cardiovascular disease (CVD) (Howitt and Garrett, 2012; Zhang
and Davies, 2016; Brown and Hazen, 2018). Interestingly, some
gut microbes can produce trimethylamine (TMA), which results
from the metabolism of fat-rich nutrients by enzymes known
as microbial TMA lyases. After being produced, TMA can
then enter the portal circulation and the liver, where it is
further processed to generate TMAO, which triggers heart and
kidney dysfunction, such as atherosclerosis, heart failure, renal
fibrosis (Brown and Hazen, 2018). Furthermore, studies now
acknowledge that CD patients frequently suffer from other
comorbid conditions, such as major depressive disorder (MDD)
and anxiety (Hueb and Loureiro, 2005; Marchi and Gurgel,
2011; Ozaki et al., 2011; Jackson et al., 2012; Suman et al.,
2017). Unsurprisingly, the gut microbiome has been associated
with the development of these neuropsychiatric disorders (Mayer
et al., 2014; Sharon et al., 2016; Dinan and Cryan, 2017; Cryan
et al., 2019). It should be noted that CD also affects the enteric
nervous system (ENS) (Meneghelli, 1985; Iantorno et al., 2007).
Unsurprisingly, the gut microbiome has been recognized to
take part in the modulation of ENS development and function
(Obata and Pachnis, 2016; Obata et al., 2020) and the ENS
is able to modulate the gut microbiome (Rolig et al., 2017).
Based on the data mentioned above, one could speculate on
whether the gut microbial community would be an additional
underpinning mechanism behind mood, cardiovascular, and ENS
changes in CD. Nevertheless, this needs to be further investigated
and corroborated.
EMERGING VIEW OF CD ON THE LIGHT
OF THE MICROBIOTA: HOW DOES THE
GUT MICROBIOTA CHANGE OUR
CURRENT VIEW OF CD?
As discussed in the introduction section, CD was previously
considered a disease resulting only from the parasite-host
interaction, but currently this view is changing due to the
inclusion of the host-microbiome as new partner in this intricate
relationship. As a result, studies are now focusing on the “vector–
parasite–microbiota interaction” (Díaz et al., 2016) and new
insights on the pathogenesis of CD are consequently emerging.
Unfortunately, the data collected so far does not precisely draw a
new picture of CD, but they indeed point toward a new direction
researchers should look at when designing new experiments.
This fact is relevant because these new studies will probably
lead to the discovery of new bacteria with essential activities for
modulation of T. cruzi infection and infection resolution. At a
later stage, these newly discovered bacteria may be manipulated
either pharmacologically or genetically (Taracena et al., 2015)
to benefit the host directly or indirectly. Identifying bacterial
communities present in the human microbiome that can act
against T. cruzi is a task that remains unresolved and therefore,
should be urgently addressed.
Throughout this review, we could observe that T. cruzi
infection results in alterations in the gut microbiota of triatomine
vectors, and this allows the parasite to progress and establish
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infection. Later, when these vectors are in contact with humans
or animals and transmit the parasite to these new hosts, T. cruzi
again induces changes in their gut microbiota. Here, we postulate
that the same process that happens in insects occurs in humans or
mice: the parasite induces changes in bacteria population. These
changes are responsible for alterations in the fecal metabolome,
impaired immune response, and poor resolution of disease,
leading to its persistence in the host. If that is the case, then the
parasite uses the same modus operandi for insects and human
hosts. Nevertheless, this hypothesis still needs to be confirmed
by future studies.
NEW PERSPECTIVES ON THE
TREATMENT OF CD: FOCUS ON
PREBIOTICS AND PROBIOTICS
Benznidazole and nifurtimox are the only available drugs used to
treat CD over the last 40 years. They are especially effective in
curing the disease when employed in the acute phase. However,
their effectiveness declines when they are used during the chronic
phase (Clayton, 2010). One of the main problems regarding
CD treatment is the timing and side effects of current therapies
(Clayton, 2010). For instance, a period of 60 days is required
for benznidazole to cure the disease at the early stage and this
drug usually has severe side effects (Clayton, 2010). This makes
adhesion to treatment and prescription of these drugs a big issue
that needs to be urgently tackled. Interestingly, benznidazole may
improve CD in association with gut microbiota modulation, as
infected children treated with this drug had decreased Prevotella
and Coprococcus (phylum Firmicutes), increase in the amount
of Dialister (phylum Firmicutes) and Enterobacteriaceae (phylum
Proteobacteria) (Robello et al., 2019).
The fact that gut microbiota is somehow related to CD
etiopathogenesis undoubtedly opens up the possibility of
development and the use of new treatments for CD. In this
regard, prebiotics – non-digestible fibers metabolized by the gut
microbiota – and probiotics – living organisms that may promote
health benefits – deserve special focus since they are already
being tested preclinically for other diseases, such as irritable
bowel syndrome (IBS) (Başturk et al., 2016; Chen et al., 2017;
Ford et al., 2018; Trifan et al., 2019), although the results are
still preliminary. Regarding CD and the use of these treatments,
there is hitherto only one report using probiotic and none using
FIGURE 2 | Microbiota-host communication pathways in CD. Firstly, T. cruzi establishes infection in the mammalian (mice and human) and insect hosts (insect
vectors). This initial step triggers gut microbiota changes in the aforementioned hosts. For example, in insects, infection leads to a decreased number of bacterial
species that possess trypanolytic activity, such as Serratia marcescens, which increases the susceptibility of the host to T. cruzi infection. In mice, changes in the
order Bacteroidales and Clostridiales, as well in the bile acid metabolism take place. In humans, there is an overall increase in Firmicutes phylum and decrease in
Bacteroides. These gut microbiota changes induced by the parasite lead to immune dysregulation and consequently poor resolution of disease. Finally, the parasite
persists in the host and is able to induce comorbidities, such as major depressive disorder (MDD).
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prebiotics. Therefore, whether they may be a valid and efficacious
treatment for CD will only be confirmed in the future. However,
probiotics as therapeutic agents against parasitic diseases have
long been proposed (Travers et al., 2011).
Gut microbiota-directed interventions hold promise for
CD treatment since some genres of bacteria can modulate
immunity, which is known to be impaired in CD patients. By
its immunomodulatory effects the host may be able to mount
a more potent immune response against T. cruzi, but whether
this is effective in preventing or eliminating infection is still
largely unknown and begs more research in the future. In
fact, only one study showed positive effects of probiotics in
experimental CD. Lactobacillus casei was administered either
orally or intraperitoneally to Swiss female mice 7 days prior to
infection with T. cruzi (Ninoa strain) and the authors observed
decreased parasitemia in the groups that received probiotics
(Garfias et al., 2008). This study raises many important issues
that deserve to be addressed: (a) the authors used a preventive
or prophylactic approach, in which probiotics were given before
infection; however, to determine what effects probiotics have in
infected subjects, studies also need to focus on the therapeutic
approach, in which probiotics are given after infection; (b)
probiotics administration led to reduced number of blood
parasites, not to the complete elimination of parasites from
the host and therefore they may not be suitable to be used as
monotherapy in the treatment of CD. Probiotics may, however,
be useful as co-therapies with standard drugs, but this still needs
to be tested. Therefore, more studies with pre- and probiotics
are required, especially because, once their effectiveness is proven
experimentally and in the clinical setting, patients may benefit
from the fact that these are low-cost and non-invasive therapies,
with fewer side effects than the current drugs used to treat CD. In
sum, an in-depth understanding of the gut microbiota in CD will
allow us to develop alternative therapeutic approaches to target
CD, such as gut microbiota-directed interventions.
CONCLUDING REMARKS AND FUTURE
PERSPECTIVES
Here we provide pre-clinical and clinical evidence that gut
microbiota may play a role in CD pathogenesis once it interferes
with infection and its resolution. It became evident that T. cruzi
induces changes in the gut microbiota and, especially in insects
and mice, this is associated with a deregulated immune response
and changed fecal metabolome, which might explain why the
parasite persists in the host (Figure 2). However, the amount
of data hitherto available is minute, and therefore, more studies
are required to support the role of gut microbiota dysfunction
in CD and its comorbidities. Future studies should test the
effects of prebiotics and probiotics on preclinical and clinical
CD to provide new treatment options for CD. Besides, they
should investigate in depth the role of gut microbiota in
CD pathogenesis, focusing on the role of microbes of certain
microbial groups, such as Firmicutes and Bacteroidetes, and its
impact in T. cruzi infection. Exploring the effects of T. cruzi
infection in humans and what microbiota changes are caused
by the parasite, as well as what species of microbes could be
modulated to control disease are also necessary. Addressing
the effects of different T. cruzi strains on microbiota changes
as well as to explore the role of skin and oral microbiota in
CD is also encouraged. Interestingly, other issues, such as the
microbiota-gut-brain axis are currently underexplored in CD and
thus deserve future attention.
A question that deserves attention is: is the dysfunction in
the microbiota responsible for neuropsychiatric comorbidities
observed in CD patients and could it be prevented or delayed
by the use of gut microbiota-directed interventions? Answering
this would allow us not only to better tackle CD but also
its comorbidities. Moreover, given that pre- and probiotics are
molecules derived from dietary compounds, such as vegetables
and fruits, it is also essential to test whether a diet rich in
these molecules could modulate CD and ameliorate disease state
in the patients.
Other gut microbiota-targeted therapies that might have
relevance to treating CD are fecal microbiota transplantation
(FMT) and synbiotics. Although appealing, no data is hitherto
available to support their use in CD patients. Furthermore, as
there are considerable differences in the microbial profile of
different portions of the gut (Donaldson et al., 2015), future
studies should also employ colon biopsies to profile the microbial
community in the intestinal mucosa of patients with CD.
As a matter of fact, funds for drug Research and Development
(R&D) on CD are scarce, which happens for many reasons
(Clayton, 2010), which are beyond the scope of this paper.
Employing the suggestions mentioned above would probably
draw the government and pharmaceutical companies’ attention
to more funding for CD, probably leading to an increase in studies
on the current topic and more elucidation on CD pathogenesis.
As a consequence, CD would be less neglected than it is today.
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GLOSSARY
Germ-free (GF) mice – mice raised without a microbiome.
Y strain of T. cruzi – A strain that is associated with low parasitemia, high mortality in mice and that can also infect neurons and glia.
Trypomastigotes – The flagellated form of T.cruzi. Trypomastigotes are released in the insect vector feces when the insect takes
a blood meal. They enter the host via mucosa or wounded sites and then infects mammalial cells, loses the flagellum and becomes
amastigotes, which replicate by binary fission. Next, they turn back to trypomastigotes, causing cell lysis and spread of infection
Polysaccharide A (PSA) – a polysaccharide from the capsule of B. fragilis that has immunomodulatory effects.
Gnotobiotic mice – mice with only certain known bacterial strains/mice colonized with known bacterial strains.
Epimastigotes – non-infective form of T. cruzi detected in the gut of insect vectors. They replicate by binary fission. At a later stage
during its life cycle, they become trypomastigotes.
Pathobiont – microorganisms of the microbiota with the potential to induce pathology (Round and Mazmanian, 2009).
Segmented filamentous bacteria (SFB) – gram-positive, spore-forming bacteria that modulates the immune system and attach to
intestinal epithelium.
Antimicrobial peptides (AMPs) – peptides from the innate immune system with activity against viruses, fungi,
parasites and bacteria.
Short-chain fatty acids (SCFAs) – bacterial metabolites, such as acetate, butyrate and propionate, derived from the fermentation of
complex indigestible fibers.
Trimethylamine (TMA) – molecule that results from the metabolism of fat-rich or TMA-rich nutrients.
Trimethylamine-N-oxide (TMAO) – a microbial metabolite derived from metabolism of trimethylamine (TMA).
Enteric nervous system (ENS) – a network formed by neurons and glia in the gastrointestinal tract.
Prebiotics – non-digestible complex fibers that are fermented by the gut bacteria and promote the growth of some bacteria and
health benefits.
Probiotics – consists of living microorganisms that confer health benefits when consumed in sufficient amounts.
Microbiota-gut-brain axis – the network composed of neural, immune and endocrine systems that mediate the effects of the gut
microbiota in the host.
Fecal Microbiota Transplantation (FMT) – one type of microbiota directed intervention that consists in transferring faucal material
from the donor to the recipient.
Secondary Bile Acids – molecules resulting from the microbes-driven metabolism of primary bile acids.
Synbiotics – association of prebiotics with probiotics.
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